Category Archives: International Collaborators

Toshiki Mizuno

Toshiki Mizuno
Division of Neurology and Gerontology
Kyoto Prefectural University of Medicine , Japan



Our research interests include diverse classes of neurological disorders, such as dementias, cerebrovascular diseases, neurodegenerative diseases, and neuromuscular diseases. We have been undertaking diagnostic studies on wide variety of dementias including Alzheimer disease, hereditary vascular dementias, and idiopathic normal pressure hydrocephalus (iNPH) by different modalities of neuroradiological investigations (SPECT, PET, and diffusion-weighted MR imaging), protein analysis on amyloid, tau, and TDP-43 proteins, and genetic analysis. On cerebrovascular diseases, we have been investigating part of the pathogenesis using fiber-tracking method, and also the therapeutic possibilities on selective cerebral hypothermia. Other research topics encompasses Parkinson disease, spinocerebellar degeneration, amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, mitochondrial diseases, Alexander disease, HTLV-I associated myelopathy and diverse types of myopathies. Our department also covers the research on cognitive impairment due to dementia and stroke and the studies on reward and dopaminergic system. In addition, our clinical service division offers genetic counseling, genetic testing, and pathological diagnosis on muscle biopsies.

Colin Masters

In 1984, Beyreuther and Masters purified and sequenced the amyloid constituent of the plaque in Alzheimer’s disease, and three years later, their group used this sequence to clone the gene encoding the Aβ amyloid peptide located on chromosome 21. These studies demonstrated that the Aβ amyloid was derived by proteolytic cleavage of a neuronal transmembrane receptor. Subsequent studies by many groups has shown that a variety of Aβ-amyloid oligomers lie at the centre of AD pathogenesis, and these are now the validated primary targets for both diagnostic and therapeutic strategies. Masters and Beyreuther therefore defined the principal molecular and genetic pathways leading to the current Aβ amyloid theory of causation of Alzheimer’s disease.
More recent studies from Masters and colleagues have also demonstrated the time-course over which the Aβ accumulates in the evolution of Alzheimer’s disease, using molecular PET- Aβ imaging, allowing the preclinical and prodromal stages to be identified during life. They have also identified some of the genetic determinants which affect the rates of cognitive decline. These insights into the natural history of Alzheimer’s disease will have a major impact on clinical trial design and provide prognostic information for subjects at risk.

Robert Friedland

Dr Friedland is a clinical and research neurologist devoted to the study of brain disorders associated with aging. He is a graduate of the City College of New York and was a student at the University of Kentucky School of Medicine before graduating from the Mount Sinai School of Medicine in New York in 1973. He completed his neurology residency at the Mount Sinai Hospital and was a Fellow in dementia and aging at the Albert Einstein College of Medicine, NY. He then worked at the University of California, Davis, and in the Research Medicine Group of the Lawrence Berkeley Laboratory of the University California, Berkeley where he served as Chief Neurologist. From 1985 to 1990 he was Deputy Clinical Director and Chief of the Section on Brain Aging and Dementia of the National Institute on Aging, National Institutes of Health of Bethesda, MD. At the CWRU School of Medicine he was Professor of Neurology, Radiology and Psychiatry and Chief of the Laboratory of Neurogeriatrics from 1990 to 2008. In December of 2008 he joined the faculty of the University of Louisville, as a Professor of Neurology. Dr. Friedland’s work has focused on clinical and biological issues in Alzheimer’s disease and related disorders. Dr. Friedland has authored or coauthored over 200 scientific publications and has current research funding from the National Institutes of Health (National Institute on Aging), as well as several Foundations, Institutes, Corporations and Families. He has had over $1,000,000 of research funding to support his work from 1985-2013.

Amy Price



Dr. Amy Price in Neurocognitive Rehabilitation and in International Missions before sustaining serious injury and years of rehabilitation. She emerged with a goal to build a bridge between research methods, research involvement and public engagement where the public is trained and empowered to be equal partners in health research.
Amy’s experience has shown her that shared knowledge, interdisciplinary collaboration and evidence-based research will shape and develop the future.

Raj Kalaria

Professor of Cerebrovascular Pathology (Neuropathology), personal chair appointed 1997
Lead PI, Newcastle Cognitive Function After Stroke (CogFAST) Longitudinal Study
Director, Neurovascular Research Group (NRG), Institute of Neuroscience
Co-ordinator, Newcastle NE ARUK Network Centre,  Alzheimer’s Research UK (ARUK)
Secretary-General, International Society for Vascular Behavioural and Cognitive Disorders (VasCog)

Gyan prakash

Gyan “John” Prakash, Ph.D.
Associate Director for International Programs
National Eye Institute
(301) 496-2234

Ante Padjen




Padjen, a neuropharmacologist at McGill University, comes to life when he discusses his orchestra. In his office on the 13th floor of the McGill medical building, he shuffles through scrapbooks that date back to I Medici’s conception in 1989. Meanwhile, in the reception area, the secretary and her computer fight for space with a harpsichord and a double bass leaning against the filing cabinets. Over the past twenty years, Padjen has had the pleasure of seeing 320 musicians of every age and medical specialty pass through the orchestra.  “Recently I received a letter from one student, a really smart guy who had several options to study medicine. He chose McGill so that he would able to play in I Medici,” he tells us. Despite the positive publicity that the orchestra lends to the Faculty of Medicine, I Medici receive no funding from McGill University(*). They are, however, provided with free practice space at the school.

Ryuichi Morishita

Division of Clinical Gene Therapy Science
Osaka University
Graduate School of Medicine
Founder and director of AnGes MG, Inc.


Morishita was born in Okayama Prefecture. He graduated from Osaka University Medical School in 1987 and finished his postdoctoral research at Stanford University School of Medicine in 1991. He was appointed as Associate Professor, Department of Geriatric Medicine, Osaka University Graduate School of Medicine in 2003.
Morishita is currently a member of the Intellectual Property Policy Committee, Structural Reform Council, Ministry of Economy, Trade and Industry. He is also a member of the Council for Science and Technology, Ministry of Education, Culture, Sports, Science and Technology. From 2003 to 2007, Morishita served as a member of the Intellectual Property Strategy Headquarters (Director General: Prime Minister).

Jaswinder Kalra

Obst. & Gynecology
Education Qualification : MD



Research in Progress

A study on Role of PCR using broad based primers in the diagnosis of perinatally acquired sepsis in the newborn (ICMR Project)

Members of Professional Bodies